- Home
- AMGN
AMGN
Amgen Inc.
as 12-20-2024 4:00pm EST
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 147.3B | IPO Year: | N/A |
| Target Price: | $329.05 | AVG Volume (30 days): | 4.7M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.83 | EPS Growth: | -44.29 |
| 52 Week Low/High: | $253.30 - $346.85 | Next Earning Date: | 02-04-2025 |
| Revenue: | $32,534,000,000 | Revenue Growth: | 21.25% |
| Revenue Growth (this year): | 20.04% | Revenue Growth (next year): | 3.41% |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Investor's Business Daily
8 hours ago
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
The Wall Street Journal
9 hours ago
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
MT Newswires
15 hours ago
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations
Investor's Business Daily
15 hours ago
Novo Crashes 20% After New Obesity Drug Misses Forecasts. Lilly, Viking, Amgen Jump.
MT Newswires
2 days ago
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating
Insider Monkey
2 days ago
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In?
Morningstar Research
2 days ago
Analyst Report: Amgen Inc.
Yahoo Finance
3 days ago
Why the Dow is suddenly in a historic funk
Compare AMGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.